[1]
Vakili, M.E.; Saleh, Z.; Kabelitz, D.; Kalantar, K. Targeting citrate carrier (CIC) in inflammatory macrophages as a novel metabolic approach in COVID-19 patients: A perspective. Endocr. Metab. Immune Disord. Drug Targets, 2022, 22(12), 1149-1153.
[http://dx.doi.org/10.2174/1871530321666210909165757] [PMID: 34503433]
[http://dx.doi.org/10.2174/1871530321666210909165757] [PMID: 34503433]
[2]
Bakhtiari, M.; Asadipooya, K. Metainflammation in COVID-19. Endocr. Metab. Immune Disord. Drug Targets, 2022, 22(12), 1154-1166.
[http://dx.doi.org/10.2174/1871530322666220104103325] [PMID: 34983356]
[http://dx.doi.org/10.2174/1871530322666220104103325] [PMID: 34983356]
[3]
Al-Jabri, Z.; Al-Reesi, I.; Al-Shizawi, N.; Al-Balushi, M.S.; Al-Jabri, A.A.; Said, E.A. Effects of bacterial metabolites on the immune system: enemies and friends. Endocr. Metab. Immune Disord. Drug Targets, 2022, 22(12), 1167-1177.
[http://dx.doi.org/10.2174/1871530321666211119150231] [PMID: 34802414]
[http://dx.doi.org/10.2174/1871530321666211119150231] [PMID: 34802414]
[4]
Sarabi, M.M.; Babaeenezhad, E.; Amini, M.; Kaviani, M.; Naghibalhossaini, F. Bilirubin and epigenetic modifications in metabolic and immunometabolic disorders. Endocr. Metab. Immune Disord. Drug Targets, 2022, 22(12), 1178-1190.
[http://dx.doi.org/10.2174/1871530321666211125102924] [PMID: 34823463]
[http://dx.doi.org/10.2174/1871530321666211125102924] [PMID: 34823463]
[5]
Babaahmadi-Rezaei, H.; Rezaei, M.; Ghaderi-Zefrehi, H.; Azizi, M.; Beheshti-Nasab, H.; Mehta, J.L. Reducing proteoglycan synthesis and nox activity by rock inhibitors: Therapeutic Targets in Atherosclerosis. Endocr. Metab. Immune Disord. Drug Targets, 2022, 22(12), 1191-1200.
[http://dx.doi.org/10.2174/1871530322666220606090801] [PMID: 35670345]
[http://dx.doi.org/10.2174/1871530322666220606090801] [PMID: 35670345]
[6]
Fattahi, M.J.; Haghshenas, M.R.; Ghaderi, A. Immunometabolism in bladder cancer microenvironment. Endocr. Metab. Immune Disord. Drug Targets, 2022, 22(12), 1201-1216.
[http://dx.doi.org/10.2174/1871530322666220104103905] [PMID: 34983357]
[http://dx.doi.org/10.2174/1871530322666220104103905] [PMID: 34983357]
[7]
Daryabor, G.; Amirghofran, Z.; Gholijani, N.; Bemani, P. Obesity and adipose tissue-derived cytokines in the pathogenesis of multiple sclerosis. Endocr. Metab. Immune Disord. Drug Targets, 2022, 22(12), 1217-1233.
[http://dx.doi.org/10.2174/1871530322666220215110041] [PMID: 35168514]
[http://dx.doi.org/10.2174/1871530322666220215110041] [PMID: 35168514]